LakeShore Biopharma Co Accounts Payable

LakeShore Biopharma Co posts a accounts payable of $50M as of March 2025. That compares with $68M in the prior-year period — down 26.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, LakeShore Biopharma Co's accounts payable was $68M. The latest reading is $50M — a 26.9% year-over-year decrease (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of LakeShore Biopharma Co's financial statement story. At $50M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LSB's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; LakeShore Biopharma Co's other metric pages and overview cover the third.